Skip to main
EKSO
EKSO logo

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc anticipates a rebound in enterprise sales, particularly from integrated delivery networks (IDNs), contingent on improvements in the macroeconomic environment. The company is making notable progress in enhancing its claims pipeline, which positions the Indego Personal exoskeleton to potentially become a significant revenue contributor in 2025 and subsequent years. Furthermore, Ekso Bionics is actively leveraging strategic partnerships to foster growth in the Indego Personal segment, indicating a proactive approach to expanding its market presence.

Bears say

Ekso Bionics Holdings Inc. reported a total revenue of $3.4 million in 1Q25, reflecting a 10% year-over-year decline from $3.8 million in 1Q24, and fell short of consensus expectations of $4.6 million. Additionally, the company has revised its revenue projections for the EksoHealth channel downward for 2025 and beyond, citing the potential adverse effects of economic uncertainty. The enterprise segment has also experienced softer revenue due to customer budget cuts, indicating challenges in maintaining sales amid a tightening financial environment.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.